Literature DB >> 12140030

Optimizing treatment of choroidal neovascularization feeder vessels associated with age-related macular degeneration.

Robert W Flower1.   

Abstract

PURPOSE: To optimize the method of treating choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).
DESIGN: Experimental study and interventional case series.
METHODS: The parameters associated with locating and then photocoagulating CNV feeder vessels were identified and optimized using published data and data derived from modeling the choroidal vasculature. Based on these optimized parameters, a prototype diagnostic/treatment system was designed that captures high-speed indocyanine green (ICG) angiogram images and facilitates analysis of the images by enhancing visualization of dye movement through CNV feeder vessels (FVs). The system also permits precise aiming and delivery of 810- nm wavelength photocoagulation laser energy to target FVs on a real-time ICG angiogram image of the choroidal vasculature. Target FVs are tracked by a joy-stick controlled laser aiming beam until an intravenously-injected high-concentration ICG dye bolus is observed to enter the target vessel, at which time the laser is fired. Proof of principle of the combined diagnosis/treatment system design for performing dye-enhanced photocoagulation (DEP) in the clinical setting and determination of the minimum DEP laser energy needed to close CNV FVs was made in 11 AMD patients requiring treatment of CNV, but for whom other treatment was not appropriate.
RESULTS: Using ICG-DEP, CNV feeder vessels were closed with single pulse laser energy, delivering as little as 0.6 to 1.8 J of energy to the fundus, producing no visible change in the fundus. Successful FV closure was usually indicated immediately by presence of incarcerated ICG dye in the vessel adjacent to the burn site. The prototype system proved relatively easy to operate. After acquiring and interpreting diagnostic angiograms and repositioning a patient in front of the device, feeder vessel DEP and treatment evaluation required 15 to 20 minutes.
CONCLUSIONS: Indocyanine green dye-enhanced photocoagulation of CNV feeder vessels, facilitated by use of a device that permits real-time visualization of the choroidal circulation while aiming the treatment laser beam, appears to minimize the amount of energy applied to the fundus and the volume of fundus tissue affected by treatment, compared with other treatment modalities. The combination diagnosis/treatment device should be useful in optimizing FV treatment and in refining and evaluating the efficacy of DEP in future clinical trials.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12140030     DOI: 10.1016/s0002-9394(02)01579-9

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

Review 1.  Age-related macular degeneration and recent developments: new hope for old eyes?

Authors:  Brid Morris; Fraser Imrie; Ana-Maria Armbrecht; Baljean Dhillon
Journal:  Postgrad Med J       Date:  2007-05       Impact factor: 2.401

2.  Dynamic indocyanine green angiography measurements.

Authors:  Timothy Holmes; Alessandro Invernizzi; Sean Larkin; Giovanni Staurenghi
Journal:  J Biomed Opt       Date:  2012-11       Impact factor: 3.170

3.  Targeting Neovascularization in Ischemic Retinopathy: Recent Advances.

Authors:  Mohamed Al-Shabrawey; Mohamed Elsherbiny; Julian Nussbaum; Amira Othman; Sylvia Megyerdi; Amany Tawfik
Journal:  Expert Rev Ophthalmol       Date:  2013-06

4.  Neovascular ingrowth site photothrombosis in choroidal neovascularization associated with retinal pigment epithelial detachment.

Authors:  Rogério A Costa; Karolinne M Rocha; Daniela Calucci; José A Cardillo; Michel E Farah
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-02-19       Impact factor: 3.117

5.  Dynamic indocyanine green angiography-guided focal thermal laser treatment of fibrotic choroidal neovascularization.

Authors:  Scott W Cousins; Srilaxmi Bearelly; Maria A Reinoso; Sulene L Chi; Diego G Espinosa-Heidmann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-08-06       Impact factor: 3.117

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.